|

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

RECRUITINGPhase 2Sponsored by Nuvation Bio Inc.
Actively Recruiting
PhasePhase 2
SponsorNuvation Bio Inc.
Started2027-03
Est. completion2030-09
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations12 sites

Summary

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria:

* Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
* IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
* Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
* Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
* Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
* Adequate hematologic and organ function
* Expected survival of ≥12 months

Key Exclusion Criteria:

* Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
* Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
* Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
* Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
* Significant functional or neurocognitive deficits, including uncontrolled seizures
* Evidence of leptomeningeal disease.
* Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of \<1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.

Conditions9

Astrocytoma, IDH-Mutant, Grade 2Astrocytoma, IDH-Mutant, Grade 3CancerGliomaGrade 2 IDH1-mutant GliomaGrade 3 IDH1-mutant GliomaIDH1-mutant GliomaOligodendrogliomaOligodendroglioma IDH-1 Mutant and 1/p19q-codeleted

Interventions1

Locations12 sites

University of California, Los Angeles
Quan Li310-825-1416quanli@mednet.ucla.edu
University of California, San Francisco
Neuro Onc New Patient Coordinator415-353-2193neurooncnewpatientcoord@ucsf.edu
Yale University
New Haven, Connecticut, 06510
University of Miami Health
Miami, Florida, 33136
Leonela Wright305-243-0864lxw612@med.miami.edu
Indiana University
NeuroOncology Clinical Trials3179634823neuroct@iu.edu

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.